1️⃣ Roche bought the AI layer for pathology

Roche agreed to acquire PathAI for $750M upfront and up to $300M in milestones. PathAI will sit inside Roche Diagnostics after closing, expected in H2 2026.

💡 Why it matters

This is diagnostics M&A with companion-diagnostic leverage. Roche is buying workflow, AI analysis and biomarker discovery capacity, not another scanner.

☕ Coffee talk

If pathology software becomes part of the companion-diagnostic stack, who still gets to call it just infrastructure?


2️⃣ Pathos bought control of a clinical MET asset

Pathos AI acquired a majority stake in DeuterOncology, adding DO-2, a phase 1 third-generation MET kinase inhibitor for MET-altered cancers.

💡 Why it matters

The asset is early, but the angle is concrete: an oncology platform using its own model to pick and buy clinical assets, then run development around them.

☕ Coffee talk

Does this prove AI can source oncology assets, or just that someone finally bought a decent MET program with better tooling?


3️⃣ Merck closed the Terns bet

Merck completed its acquisition of Terns after a $53-per-share tender offer, taking in TERN-701, an oral allosteric BCR::ABL1 inhibitor for CML.

💡 Why it matters

This turns a March deal into owned pipeline. Merck is accepting a near-term R&D charge to add a hematology asset with Breakthrough Therapy status.

☕ Coffee talk

How many more early oncology assets does Merck need before Keytruda feels less like the clock in the room?